While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET James Markmann - Corporate Participant Michael ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental ...

Bullseye is a celebration of the best of arts and culture in public radio form. Host Jesse Thorn sifts the wheat from the chaff to bring you in-depth interviews with the most revered and ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.